Immatics N.V. (NASDAQ:IMTX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $20.80.
A number of research analysts recently weighed in on the stock. Weiss Ratings cut shares of Immatics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. TD Cowen initiated coverage on Immatics in a report on Tuesday, April 28th. They set a “buy” rating on the stock. Chardan Capital reissued a “buy” rating and set a $25.00 price target on shares of Immatics in a report on Tuesday, May 19th. Jefferies Financial Group initiated coverage on Immatics in a research report on Monday, March 16th. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, Wall Street Zen lowered Immatics from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd.
Read Our Latest Report on Immatics
Immatics Price Performance
Immatics (NASDAQ:IMTX – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.08). The firm had revenue of $8.81 million during the quarter, compared to the consensus estimate of $9.79 million. Immatics had a negative return on equity of 47.36% and a negative net margin of 572.35%. On average, sell-side analysts anticipate that Immatics will post -1.67 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMTX. Bank of America Corp DE grew its holdings in Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after buying an additional 2,231 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Immatics by 31.5% in the second quarter. JPMorgan Chase & Co. now owns 198,769 shares of the company’s stock worth $1,069,000 after buying an additional 47,590 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Immatics by 105.2% in the second quarter. BNP Paribas Financial Markets now owns 78,123 shares of the company’s stock worth $420,000 after buying an additional 40,058 shares in the last quarter. Engineers Gate Manager LP bought a new position in shares of Immatics during the second quarter worth $124,000. Finally, Sofinnova Investments Inc. boosted its position in shares of Immatics by 44.1% during the second quarter. Sofinnova Investments Inc. now owns 2,240,528 shares of the company’s stock worth $12,054,000 after acquiring an additional 686,224 shares during the last quarter. 64.41% of the stock is currently owned by institutional investors.
About Immatics
Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.
At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.
Featured Articles
- Five stocks we like better than Immatics
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.
